North America DNA vaccines market will grow progressively at a CAGR of 42.49% in terms of revenue for the forecast period of 2019-2027.
The United States DNA vaccines market is mainly driven by the enhancement in the prevalence rate of chronic and infectious diseases such as ZICA, HIV, HPV and cardiovascular diseases, and the investments made by private foundations such as the Bill and Melinda Gates Foundation. The mortality rate due to chronic and infectious diseases has increased in the country and reached about 360,000 per year.
Furthermore, the focus and interest of government agencies like the National Institute of Health, the National Institute of Allergy and Infectious Diseases, and others, that are engaged in the development of DNA-based vaccines have also helped to promote the market growth in the United States.
The United States National Institute of Health is being paid substantial funds for DNA vaccine research & development activities. The institute has also established a new vaccine research center in the country. The Bill and Melinda Gates Foundation has made an investment of about $100 million in Moderna Therapeutics for developing DNA vaccines, which will enhance the growth and advancement for the adoption of DNA vaccines for human as well as animal diseases.
Few of the prime players in this market are GlaxoSmithKline, Inc., Inovio Pharmaceuticals, Inc., Madison Vaccines, Incorporated (MVI), Merck & Co., Merial Limited (acquired by Boehringer Ingelheim), Novartis AG and Sanofi.
Key Topics Covered:
1. North America DNA Vaccines Market - Summary
2. Industry Outlook
2.1. Market Definition
2.2. Porter's Five Forces Outlook
2.3. Vendor Scorecard
2.4. Value Chain Outlook
2.5. Key Insights
2.6. Regulatory Framework
2.7. Key Buying Outlook
2.8. Market Drivers
2.8.1. Surge in New Vaccine Development
2.8.2. Rise in the Usage of DNA Vaccines for Animal Healthcare
2.8.3. Rising Prevalence of Chronic and Infectious Diseases
2.9. Market Restraints
2.9.1. Lack of Legal and Ethical Framework
2.9.2. Stringent Government Regulations
2.10. Market Opportunities
2.10.1. Growing Demand for Gene Therapy
2.10.2. Steady Vaccines Are Easy to Store and Transport
2.10.3. Increasing Number of Clinical Trials on Humans
2.11. Market Challenges
2.11.1. Variation in the Regulatory Pathway and the Points of Consideration Regarding Environmental Valuation
3. DNA Vaccines Market Outlook - by Type
3.1. Animal DNA Vaccine
3.2. Human DNA Vaccine
4. DNA Vaccines Market Outlook - by Application
4.1. Human Disease
4.2. Veterinary Disease
5. DNA Vaccines Market Outlook - by Technology
5.1. Plasmid DNA Vaccines
5.2. Plasmid DNA Delivery
6. DNA Vaccines Market Outlook - by Region
6.1. North America
6.1.1. Country Analysis
126.96.36.199. The United States
7. Competitive Landscape
7.1. Astellas Pharma, Inc.
7.2. Dendreon Corporation (Acquired by Sanpower Group)
7.3. Eli Lilly and Company
7.4. Eurogentec S.A.
7.5. Glaxosmithkline, Inc.
7.6. Inovio Pharmaceuticals, Inc.
7.7. Madison Vaccines, Incorporated (Mvi)
7.8. Merck & Co.
7.9. Merial Limited (Acquired by Boehringer Ingelheim)
7.10. Novartis AG
7.13. Vical, Incorporated
7.14. Xenetic Biosciences, Inc.
7.15. Zoetis, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/lmntbf